Efficacy and precautions after using Stiripentol in children

Stiripentol is one of the earliest drugs used in the world to treat refractory epilepsy in infants and children. It is often combined with valproic acid, clobazam, etc. as an important part of the management plan for Dravet syndrome. Overseas experience shows that it can significantly reduce the number of epileptic seizures in some children by enhancing gamma-aminobutyric acid (GABA) inhibitory signals and stabilizing nerve excitability. As the understanding of the pathogenesis of childhood epilepsy deepens, stiripentol is increasingly recognized globally as an anti-epileptic option with long-term management value.

In most children, the efficacy of stiripentol is manifested in the reduction of intermittent seizures, shortened duration, and indirect improvement in mood and sleep quality, which makes it listed as a highly recommended combination therapy in clinical guidelines from many countries. Because children's brain development is immature and the stability of epilepsy control is critical for cognitive, language, and motor development, rational use of stiripentol has positive long-term implications.

However, there are some important things that must be paid attention to when using stiripentol in children. First of all, stiripentol has metabolic interactions with a variety of anti-epileptic drugs. For example, it can affect the metabolic level of clobazam. Therefore, when adjusting the dose in children, professional physicians need to comprehensively evaluate the combined drug concentration to avoid adverse reactions caused by too fast or too slow metabolism. Secondly, stiripentol may cause symptoms such as loss of appetite, mild digestive discomfort, or temporary fatigue. Parents need to closely observe the child's eating habits, sleep patterns, and mental state, and consult the attending doctor to determine whether the dosage needs to be adjusted when necessary.

In addition, stiripentol is more sensitive to the effects of stiripentol on children with lower body weight and immature liver function. Therefore, regular monitoring of liver function, blood routine and drug blood concentration should be carried out during treatment to ensure a balance between safety and efficacy.

Reference materials:https://www.diacomit.com/